---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-028647"
form_type: "8-K"
ticker: "JANX"
cik: "0001817713"
company_name: "Janux Therapeutics, Inc."
filed_at: "2024-03-08T23:59:59+00:00"
generated_at: "2026-06-05T00:41:56.072534+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Janux reports $344M year-end cash; Q4 net loss $11.8M; positive Phase 1 JANX007/JANX008 data

## Summary
- Year-end cash & investments $344M; net loss $58.3M for FY 2023 vs $63.1M in 2022.
- Raised ~$320.2M net in March 2024 underwritten offering to fund clinical pipeline.
- Phase 1 JANX007 in mCRPC: 83% PSA50 at first step dose ≥0.2mg; no CRS > Grade 2.
- Phase 1 JANX008: NSCLC subject achieved RECIST PR with 100% target lesion reduction, no CRS.
- Co-founder Dr. Tommy DiRaimondo promoted to CSO; JANX007 update expected 2H 2024.

## SEC filing metadata
- accession: 0000950170-24-028647
- form_type: 8-K
- ticker: JANX
- cik: 0001817713
- company_name: Janux Therapeutics, Inc.
- filed_at: 2024-03-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1817713/000095017024028647/0000950170-24-028647-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1817713/000095017024028647/janx-20240308.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-028647
- JSON: https://secwatch.observer/filing/0000950170-24-028647.json
- Plain text: https://secwatch.observer/filing/0000950170-24-028647.txt

## Key facts
- Earnings Releases
  Janux Therapeutics, Inc. reported the fourth quarter and full year ended December 31, 2023 results: net income Net loss was $11.8 million for the quarter and $58.3 million for the year ended December 31, 2023.
  - Period: the fourth quarter and full year ended December 31, 2023
  - Net income: Net loss was $11.8 million for the quarter and $58.3 million for the year ended December 31, 2023
  - Result: reported results
  source text: Janux Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1817713/000095017024028647/0000950170-24-028647-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.